A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).

Peter Schmid,Javier Cortes,Mark E. Robson,Hiroji Iwata,Roberto Hegg,Marina Nechaeva,Binghe Xu,Sunil Verma,V. Haddad,Esteban Rodrigo Imedio,Gaia Schiavon,Andrew Foxley,Yeon Hee Park

A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).

2020

Peter Schmid
Javier Cortes
Mark E. Robson
Hiroji Iwata
Roberto Hegg
Marina Nechaeva
Binghe Xu
Sunil Verma
V. Haddad
Esteban Rodrigo Imedio
Gaia Schiavon
Andrew Foxley
Yeon Hee Park

TPS1109Background: Therapeutic options for patients with metastatic triple-negative breast cancer (TNBC) are limited to sequential chemotherapy, although recent advances with novel agents have been...

Keywords:

Oncology
Internal medicine
Paclitaxel
Triple-negative breast cancer
first line treatment
Pathology
Medicine
Breast cancer
novel agents
sequential chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations